Send to

Choose Destination
J Rheumatol. 2019 Apr 15. pii: jrheum.180897. doi: 10.3899/jrheum.180897. [Epub ahead of print]

Anti-CCP3.1 and Anti-CCP-IgA Are Associated with Increasing Age in Individuals Without Rheumatoid Arthritis.

Author information

From the Division of Rheumatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA; Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, USA; Division of Rheumatology, Veteran Affairs Nebraska Western Iowa Health Care System, Omaha, NE, USA; Department of Research, INOVA Diagnostics, San Diego, CA, USA; Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Division of Rheumatology, Scripps Green Hospital, La Jolla, CA, USA; Department of Immunology, Benaroya Research Institute at Virginia Mason, Seattle, WA, USA; Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, USA. This work was supported by the National Institutes of Health [grant numbers AR066712, AI110503, AI101981, and T32AR007534], and a Rheumatology Research Foundation Resident Research Preceptorship Award. Contents are the authors' sole responsibility and do not necessarily represent official NIH views. Address correspondence to M. Kristen Demoruelle, MD, PhD University of Colorado Denver School of Medicine Division of Rheumatology 1775 Aurora Court, Mail Stop B-115 Aurora, CO 80045 Email:



We investigated the association of age and anti-cyclic citrullinated peptide (CCP) antibodies in subjects without RA.


Serum was tested for anti-CCP3.1 (IgG/IgA) in 678 first-degree relatives (FDRs) of RA patients and 330 osteoarthritis (OA) subjects. Individual isotypes (anti-CCPIgA and anti-CCP-IgG) were also tested in all FDRs.


In FDRs, increasing age was significantly associated with positivity for anti-CCP3.1 (per year, OR=1.03) and anti-CCP-IgA (per year, OR=1.05) but not anti-CCPIgG. In FDRs and OA subjects, anti-CCP3.1 prevalence was significantly increased after age 50.


Increasing age in individuals without RA should be considered in the interpretation of anti-CCP3.1 positivity.


Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center